Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Aug;72(2):339–343. doi: 10.1038/bjc.1995.335

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.

L M Ching 1, Z F Xu 1, B H Gummer 1, B D Palmer 1, W R Joseph 1, B C Baguley 1
PMCID: PMC2033997  PMID: 7640215

Abstract

The investigational anti-tumour agent, 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA), an analogue of flavone acetic acid (FAA), has been scheduled for clinical evaluation. Like FAA, 5,6-MeXAA exhibits excellent experimental anti-tumour activity and is an efficient inducer of cytokines in mice. We have examined the effect of pharmacological suppression of tumour necrosis factor (TNF) production on the anti-tumour activity of 5,6-MeXAA, taking advantage of previous observations that TNF production in response to endotoxin in vitro is inhibited by thalidomide. Thalidomide at doses of between 8 and 250 mg kg-1 efficiently suppressed serum TNF activity in response to 5,6-MeXAA at its optimal TNF inducing dose of 55 mg kg-1. Suppression was achieved when thalidomide was administered at the same time as, or up to 4 h before, 5,6-MeXAA. Under conditions in which TNF activity was suppressed, the degree of tumour haemorrhagic necrosis and the proportion of cures in the subcutaneous Colon 38 tumour were increased. In mice administered thalidomide (100 mg kg-1) together with 5,6-MeXAA (30 mg kg-1), complete tumour regression was obtained in 100% of mice, as compared with 67% in mice receiving 5,6-MeXAA alone. The results suggest a possible new application for thalidomide and pose new questions about the action of 5,6-MeXAA and related compounds.

Full text

PDF
339

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baguley B. C., Calveley S. B., Crowe K. K., Fray L. M., O'Rourke S. A., Smith G. P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol. 1989 Feb;25(2):263–269. doi: 10.1016/0277-5379(89)90018-7. [DOI] [PubMed] [Google Scholar]
  2. Bibby M. C., Double J. A., Loadman P. M., Duke C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst. 1989 Feb 1;81(3):216–220. doi: 10.1093/jnci/81.3.216. [DOI] [PubMed] [Google Scholar]
  3. CASINI G., FERAPPI M. PREPARAZIONE DI UNO DEGLI ANTIPODI OTTICI DELLA 2-FTALIMMIDOGLUTARIMMIDE. Farmaco Sci. 1964 Jun;19:563–565. [PubMed] [Google Scholar]
  4. Ching L. M., Joseph W. R., Crosier K. E., Baguley B. C. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 1994 Feb 15;54(4):870–872. [PubMed] [Google Scholar]
  5. Ching L. M., Joseph W. R., Zhuang L., Baguley B. C. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol. 1994;35(2):153–160. doi: 10.1007/BF00686639. [DOI] [PubMed] [Google Scholar]
  6. Ching L. M., McKeage M. J., Joseph W. R., Kestell P., Zwi L. J., Baguley B. C. Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid. Cancer Chemother Pharmacol. 1991;28(6):414–419. doi: 10.1007/BF00685816. [DOI] [PubMed] [Google Scholar]
  7. Ehninger G., Eger K., Stuhler A., Schuler U. Thalidomide--the need for a new clinical evaluation of an old drug. Bone Marrow Transplant. 1993;12 (Suppl 3):S26–S28. [PubMed] [Google Scholar]
  8. Fabro S., Smith R. L., Williams R. T. Toxicity and teratogenicity of optical isomers of thalidomide. Nature. 1967 Jul 15;215(5098):296–296. doi: 10.1038/215296a0. [DOI] [PubMed] [Google Scholar]
  9. Finlay G. J., Wilson W. R., Baguley B. C. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol. 1986 Jun;22(6):655–662. doi: 10.1016/0277-5379(86)90162-8. [DOI] [PubMed] [Google Scholar]
  10. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  11. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994 Aug 18;370(6490):555–557. doi: 10.1038/370555a0. [DOI] [PubMed] [Google Scholar]
  12. Mace K. F., Hornung R. L., Wiltrout R. H., Young H. A. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res. 1990 Mar 15;50(6):1742–1747. [PubMed] [Google Scholar]
  13. Mahadevan V., Malik S. T., Meager A., Fiers W., Lewis G. P., Hart I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990 Sep 1;50(17):5537–5542. [PubMed] [Google Scholar]
  14. McCormick P. A., Scott F., Epstein O., Burroughs A. K., Scheuer P. J., McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol. 1994 Oct;21(4):496–499. doi: 10.1016/s0168-8278(94)80092-8. [DOI] [PubMed] [Google Scholar]
  15. McGeehan G. M., Becherer J. D., Bast R. C., Jr, Boyer C. M., Champion B., Connolly K. M., Conway J. G., Furdon P., Karp S., Kidao S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. doi: 10.1038/370558a0. [DOI] [PubMed] [Google Scholar]
  16. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993 Jun 1;177(6):1675–1680. doi: 10.1084/jem.177.6.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pratesi G., Rodolfo M., Rovetta G., Parmiani G. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer. 1990;26(10):1079–1083. doi: 10.1016/0277-5379(90)90056-y. [DOI] [PubMed] [Google Scholar]
  18. Rewcastle G. W., Atwell G. J., Baguley B. C., Calveley S. B., Denny W. A. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem. 1989 Apr;32(4):793–799. doi: 10.1021/jm00124a012. [DOI] [PubMed] [Google Scholar]
  19. Rewcastle G. W., Atwell G. J., Li Z. A., Baguley B. C., Denny W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem. 1991 Jan;34(1):217–222. doi: 10.1021/jm00105a034. [DOI] [PubMed] [Google Scholar]
  20. Rewcastle G. W., Kestell P., Baguley B. C., Denny W. A. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst. 1990 Mar 21;82(6):528–529. doi: 10.1093/jnci/82.6.528. [DOI] [PubMed] [Google Scholar]
  21. Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991 Mar 1;173(3):699–703. doi: 10.1084/jem.173.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Silva S. R., Viana P. C., Lugon N. V., Hoette M., Ruzany F., Lugon J. R. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67(3):270–273. doi: 10.1159/000187978. [DOI] [PubMed] [Google Scholar]
  23. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989 Jul 5;81(13):1005–1013. doi: 10.1093/jnci/81.13.1005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES